IMBRUVICA® – Available at Onco360
Onco360 has been selected to the extremely limited distribution network of
Specialty Pharmacies for IMBRUVICA (ibrutinib).
Refer Your IMBRUVICA Patients to Onco360
The New IMBRUVICA® pill is now available as a one-pill, once-a-day treatment. The new IMBRUVICA is the same medication, at the same dose, with the same active ingredient. For most of your patients, this will mean taking fewer pills a day.
e-Prescribe
Oncomed Dba Onco360 or
NPI# 1679618151
Fax
877.662.6355
How to Refer
Call
IMBRUVICA Indications
IMBRUVICA (ibrutinib) has been approved by the FDA for the four following indications and is available for prescription order through Onco360
| APPROVED INDICATIONS1 | RECOMMENDED DOSAGE2 |
| Chronic lymphocytic leukemia (CLL) patients | 420 mg orally once daily |
| CLL patients with 17p deletion | 420 mg orally once daily |
| Waldenström’s macroglobulinemia (WM) patients | 420 mg orally once daily |
| Mantle cell lymphoma (MCL) patients who have received at least one prior treatment |
560 mg orally once daily |
| Marginal zone lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy | 560 mg taken orally once daily |
Eligible patients who are prescribed IMBRUVICA may receive access support through the YOU&i Access Program. More information is available at: 877-877-3536 or at https://www.imbruvica.com/.
For more information about IMBRUVICA, please visit IMBRUVICA.com.
Reference:
- www.imbruvica.com
- Imbruvica Prescribing Information
All rights in the product names, trade names, or logos of all third-party products, whether or not appearing with the registered trademark symbol, belong exclusively to their respective owners.